Co-Diagnostics (LTS:0A50) Cyclically Adjusted Book per Share: $57.29 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A50 Co-Diagnostics Inc LTS:0A50
63 GF Score
Price $1.52
GF Value $2.17
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Cyclically Adjusted Book per Share?

Co-Diagnostics LTS:0A50 -1.94% 63 Cyclically Adjusted Book per Share is $57.29 as of Mar. 2026. GuruFocus rates LTS:0A50 with a GF Score™ of 63/100 and a GF Value™ of $2.17 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Co-Diagnostics's adjusted book value per share for the three months ended in Mar. 2026 was $4.454. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $57.29 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-03), Co-Diagnostics's current stock price is $1.52. Co-Diagnostics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $57.29. Co-Diagnostics's Cyclically Adjusted PB Ratio of today is 0.03.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Co-Diagnostics was 0.25. The lowest was 0.02. And the median was 0.05.


Co-Diagnostics  (LTS:0A50) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Co-Diagnostics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.52/57.29
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Co-Diagnostics was 0.25. The lowest was 0.02. And the median was 0.05.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Co-Diagnostics Cyclically Adjusted Book per Share Related Terms


Co-Diagnostics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Cyclically Adjusted Book per Share Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 58.20

Co-Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 54.91 58.20 57.29

LTS:0A50 vs HSCS, NVNO, SINT: Cyclically Adjusted Book per Share Comparison

For the Medical Devices subindustry, Co-Diagnostics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics Cyclically Adjusted PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Cyclically Adjusted PB Ratio falls into.


LTS:0A50
63GF Score
Co-Diagnostics Inc LTS:0A50
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Co-Diagnostics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Co-Diagnostics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.454/330.2130*330.2130
=4.454

Current CPI (Mar. 2026) = 330.2130.

Co-Diagnostics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 -8.029 241.432 -10.981
201703 -9.903 243.801 -13.413
201706 -11.783 244.955 -15.884
201709 12.687 246.819 16.974
201712 9.370 246.524 12.551
201803 6.241 249.554 8.258
201806 3.017 251.989 3.954
201809 0.301 252.439 0.394
201812 -2.457 251.233 -3.229
201903 9.813 254.202 12.747
201906 8.417 256.143 10.851
201909 5.768 256.759 7.418
201912 3.005 256.974 3.861
202003 20.948 258.115 26.799
202006 35.752 257.797 45.795
202009 56.204 260.280 71.305
202012 70.060 260.474 88.818
202103 79.767 264.877 99.443
202106 90.619 271.696 110.136
202109 104.006 274.310 125.202
202112 119.321 278.802 141.324
202203 130.375 287.504 149.742
202206 128.305 296.311 142.985
202209 130.887 296.808 145.618
202212 111.293 296.797 123.823
202303 108.355 301.836 118.542
202306 100.811 305.109 109.106
202309 97.348 307.789 104.440
202312 82.547 306.746 88.862
202403 75.123 312.332 79.424
202406 68.043 314.175 71.516
202409 59.947 315.301 62.782
202412 48.888 315.605 51.151
202503 42.825 319.799 44.220
202506 34.111 322.561 34.920
202509 24.815 324.800 25.229
202512 9.847 324.054 10.034
202603 4.454 330.213 4.454

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $57.29 mean?
Co-Diagnostics (LTS:0A50) has a Cyclically Adjusted Book per Share of $57.29 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Co-Diagnostics and its competitors.
Is Co-Diagnostics' Cyclically Adjusted Book per Share too high?
Co-Diagnostics' current Cyclically Adjusted Book per Share is $57.29. Overall, Co-Diagnostics has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Cyclically Adjusted Book per Share compare to HSCS and NVNO?
Co-Diagnostics' Cyclically Adjusted Book per Share of $57.29 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Book per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current Cyclically Adjusted Book per Share is $57.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Co-Diagnostics (LTS:0A50) is currently considered Possible Value Trap. The stock's GF Value™ is $2.17, compared to a current price of $1.52 — trading 30% below its estimated fair value. The current Cyclically Adjusted Book per Share is $57.29. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Co-Diagnostics (LTS:0A50), the current Cyclically Adjusted Book per Share is $57.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (LTS:0A50) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be undervalued. The current stock price of $1.52 is trading 30% below its estimated GF Value™ of $2.17. GuruFocus considers Co-Diagnostics to be Possible Value Trap.

Key valuation signals for LTS:0A50:

  • Cyclically Adjusted Book per Share: $57.29
  • GF Value™: $2.17 vs. price of $1.52 (30% below fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the LTS:0A50 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Co-Diagnostics Business Description

Other Exchanges CODX:USA
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score

Get the complete analysis for LTS:0A50

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.52
Price
$2.17
GF Value